7.69
price up icon1.85%   0.14
after-market After Hours: 7.65 -0.04 -0.52%
loading
Aurinia Pharmaceuticals Inc stock is traded at $7.69, with a volume of 1.12M. It is up +1.85% in the last 24 hours and down -17.93% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
See More
Previous Close:
$7.55
Open:
$7.73
24h Volume:
1.12M
Relative Volume:
0.84
Market Cap:
$1.10B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-14.51
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-7.79%
1M Performance:
-17.93%
6M Performance:
+35.63%
1Y Performance:
-0.65%
1-Day Range:
Value
$7.61
$7.78
1-Week Range:
Value
$7.52
$8.27
52-Week Range:
Value
$4.71
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Name
Aurinia Pharmaceuticals Inc
Name
Phone
250-744-2487
Name
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Employee
300
Name
Twitter
@AuriniaPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
7.69 1.10B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.26 109.26B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
703.43 77.30B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.19 39.78B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.01 32.38B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.67 27.25B 3.30B -501.07M 1.03B -2.1146

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-04-22 Downgrade Oppenheimer Outperform → Perform
May-05-22 Resumed Cantor Fitzgerald Overweight
Dec-10-21 Upgrade Oppenheimer Perform → Outperform
Oct-28-21 Downgrade Oppenheimer Outperform → Perform
Jan-25-21 Reiterated H.C. Wainwright Buy
Nov-03-20 Reiterated H.C. Wainwright Buy
Jun-17-20 Initiated BTIG Research Buy
May-05-20 Initiated Cowen Outperform
Jan-10-20 Initiated Jefferies Buy
Dec-16-19 Reiterated H.C. Wainwright Buy
Mar-16-18 Reiterated Cantor Fitzgerald Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Oct-30-17 Reiterated H.C. Wainwright Buy
May-18-17 Reiterated H.C. Wainwright Buy
Apr-11-17 Initiated Cantor Fitzgerald Overweight
Mar-22-17 Reiterated FBR & Co. Outperform
Dec-30-16 Reiterated H.C. Wainwright Buy
Aug-17-16 Reiterated H.C. Wainwright Buy
Jun-30-16 Initiated H.C. Wainwright Buy
May-08-15 Initiated MLV & Co Buy
View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

pulisher
Jan 14, 2025

AUPH: Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - StockNews.com

Jan 14, 2025
pulisher
Jan 12, 2025

Barclays PLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Jan 12, 2025
pulisher
Jan 09, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Long Term Trading Analysis for (AUPH) - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 08, 2025

New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights - GlobeNewswire Inc.

Jan 08, 2025
pulisher
Jan 03, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH shareholders incur further losses as stock declines 5.2% this week, taking five-year losses to 57% - Simply Wall St

Jan 03, 2025
pulisher
Jan 03, 2025

Franklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace

Jan 03, 2025
pulisher
Dec 28, 2024

Barclays PLC Acquires 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Dec 28, 2024
pulisher
Dec 24, 2024

Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals

Dec 24, 2024
pulisher
Dec 24, 2024

State Street Corp Has $21.59 Million Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Dec 24, 2024
pulisher
Dec 19, 2024

(AUPH) On The My Stocks Page - Stock Traders Daily

Dec 19, 2024
pulisher
Dec 15, 2024

Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN

Dec 11, 2024
pulisher
Dec 11, 2024

Exploring Three High Growth Tech Stocks In The United States - Simply Wall St

Dec 11, 2024
pulisher
Dec 11, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St

Dec 11, 2024
pulisher
Dec 10, 2024

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN

Dec 10, 2024
pulisher
Dec 10, 2024

Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK

Dec 10, 2024
pulisher
Dec 09, 2024

Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India

Dec 09, 2024
pulisher
Dec 09, 2024

Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia

Dec 09, 2024
pulisher
Dec 08, 2024

(AUPH) Investment Analysis - Stock Traders Daily

Dec 08, 2024
pulisher
Dec 06, 2024

While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance

Dec 06, 2024
pulisher
Dec 03, 2024

We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St

Dec 03, 2024
pulisher
Dec 01, 2024

PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat

Nov 30, 2024
pulisher
Nov 25, 2024

Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Nov 25, 2024
pulisher
Nov 21, 2024

Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail

Nov 21, 2024
pulisher
Nov 20, 2024

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise

Nov 18, 2024
pulisher
Nov 17, 2024

(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 17, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise

Nov 15, 2024
pulisher
Nov 15, 2024

Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com

Nov 15, 2024

Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.20
price up icon 9.31%
$30.74
price up icon 2.36%
$72.46
price up icon 0.74%
$361.64
price down icon 0.84%
biotechnology ONC
$201.72
price up icon 0.36%
$113.67
price up icon 1.10%
Cap:     |  Volume (24h):